A leader from the risk-based quality management solutions provider will discuss the growing interest in the technology, during this year’s SCOPE event.
The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
This year brought the ‘biggest momentum shift’ in the adoption of risk-based approach to trial management in the clinical research industry, says CluePoints executive.
Notocord, an Instem company, will provide data acquisition and analysis services to a research and innovation program to improve risk prediction of cardiovascular adverse events.
The MA-based CRO Veristat is partnering with Triumph Research Intelligence to provide centralized and risk-based monitoring solutions to improve clinical trial compliance.
Comprehend, a clinical intelligence software company, has packaged its clinical trial risk detection and management service offerings to accommodate the needs of mid-sized CROs.
